Hepatitis C Diagnostic Summit 2016

Welcome – Jonathan Mermin, MD, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC
Opening remarks & Setting the Stage for the Summit – John Ward, MD, Division of Viral Hepatitis, CDC

Session I: Diagnosis and Management of Current HCV Infection – From HCV Testing to Cure 
Moderators: Michael Fried, MD and Daniel Johnson, MD 
 

Testing for diagnosis of current HCV infection
Lesley Miller, MD, Emory University School of Medicine/Grady Hospital
Testing for management and monitoring of anti-viral therapy
Adrian Di Bisceglie, MD, Saint Louis University School of Medicine, St Louis, MO
Testing for relapse versus re-infection and on-going exposures
Brian Edlin, MD, Medical officer, NCHHSTP, CDC
Testing of high-risk and special populations
W. Ray Kim, MD, Stanford University Medical Center, Stanford, CA
HCV national surveillance
Scott Holmberg, MD, Division of Viral Hepatitis, CDC
Roundtable of speakers with Q&As

Session II: HCV Diagnostics: the Clinical and Public Health Laboratory Setting – Policy, Practice and Data 
Moderators: Bernie Branson, MD and Jeffrey Engel, MD 
 

Testing practices and platforms, and challenges in implementing CDC’s updated hepatitis C testing guidelines
LabCorp – Christos Petropoulos, PhD
Quest Diagnostics – Rick Pesano, MD, PhD
Cleveland Clinic – Belinda Yen-Lieberman, PhD
Use of commercial lab data for public health action
Susan Hariri, PhD, Division of Viral Hepatitis, CDC
Roundtable of speakers with Q&As

Session III: Expanding Access to Quality HCV Diagnostics Globally Especially in Resource-limited Settings 
Moderators: Claudia Denkinger, MD and John Ward, MD 
 

Overview of global gaps in diagnostics
Francisco Averhoff, MD, Division of Viral Hepatitis, CDC
Efforts to improve and make HCV Diagnostics affordable globally
Claudia Denkinger, MD, Tuberculosis and Hepatitis Program, FIND
The pursuit of ‘good enough’ in hepatitis C diagnostics
Camila Graham, MD, Beth Israel Deaconess Medical Center, Boston, MA
MSF experience with HCV screening, care and monitoring
Anne Loarec, MD, Médecins Sans Frontières / Doctors without Borders
Development of WHO standards for HCV NATs
Julia Kreß, PhD, Paul Ehrlich Institute
CDC’s efforts in improving diagnostics: development of proficiency panels
Saleem Kamili, PhD, Division of Viral Hepatitis, CDC
Roundtable of speakers with Q&As
Closing remarks
John Ward, MD, Division of Viral Hepatitis, CDC

Opening remarks – John Ward, MD, Division of Viral Hepatitis, CDC

Session IV: HCV Diagnostics – New and Improved Technologies
Moderators: Saleem Kamili, PhD and Steve Lovell, PhD
 

Current diagnostic landscape in HCV
Bernie Branson, MD, Scientific Affairs
HCV core antigen Assay
George Dawson, PhD, Abbott
Point-of-care HCV antibody assays
Michael Reed, PhD, Orasure
Point-of-care HCV core antigen test development
Hong Qi, PhD, Qoo labs
Point-of-care HCV RNA test
Tanya Applegate, PhD, Kirby Institute, UNSW, AU
Integrated testing for multiple pathogens – Virome analysis
Christiane Honisch, PhD, Illumina
Roundtable of speakers with Q&As

Session V: U.S. Public Health role in HCV Detection, Investigation and Response 
Moderator:  Carolyn Wester, MD, MPH 
 

Public Health Lab Capacity in the United States
Anne Gaynor, PhD, Association of Public Health Laboratories
Challenges in using Laboratory Developed Tests in HCV Diagnostics
Monica Parker, PhD, New York State Department of Health
Regulatory issues in diagnostic development
Steve Lovell, PhD, FDA
Cost-effectiveness of various HCV testing strategies
Michael Chapko, PhD, University of Washington
Roundtable of speakers with Q/A

Session V: U.S. Public Health role in HCV Detection, Investigation and Response 
Moderator: Greg Armstrong, MD
 

Evolving a state laboratory diagnostic capacity during an HCV outbreak
Fengxiang Gao, PhD, New Hampshire State Department of Health
Next Generation Sequencing Technology
Lilia Ganova-Raeva, PhD, Division of Viral Hepatitis, CDC
GHOST – outbreak investigations and molecular surveillance
Yury Khudyakov, PhD, Division of Viral Hepatitis, CDC
Implementation of GHOST – a Pilot site
Linda Thomas, MS, Tennessee State Department of Health
Roundtable of speakers with Q/A
Panel Discussion: Key programmatic and policy issues impacting health departments in regards to hepatitis C
Carolyn Wester, MD, MPH; Doug Thoroughman, PhD, MS; Liisa M. Randall, PhD
Wrap-up and closing remarks
John Ward, MD, Division of Viral Hepatitis, CDC

Hepatitis C Diagnostic Summit Brochure Cdc-pdf[PDF – 4 pages]

Speakers and Moderators

Tanya Applegate, PhD
Francisco Averhoff, MD
Adrian Di Bisceglie, MD
Bernie Branson, MD
Michael Chapko, PhD
George Dawson, PhD
Claudia Denkinger, MD
Brian Edlin, MD
Jeffrey Engel, MD
Michael Fried, MD
Anne Gaynor, PhD
Lilia Ganova-Raeva, PhD
Fengxiang Gao, PhD
Camila Graham, MD
Susan Hariri, PhD
Scott Holmberg, MD
Christiane Honisch, PhD
Daniel Johnson, MD
Saleem Kamili, PhD
Yury Khudyakov, PhD

W. Ray Kim, MD
Maja Kodani, PhD
Julia Kreß, PhD
Anne Loarec, MD
Steve Lovell, PhD
Lesley Miller, MD
Monica Parker, PhD
Rick Pesano, MD, PhD
Christos Petropoulos, PhD
Hong Qi, PhD
Liisa M. Randall, PhD.
Michael Reed, MD
Linda Thomas, MS
Doug Thoroughman, PhD, MS
John W. Ward, MD
Carolyn Wester, MD, MPH
Belinda Yen-Lieberman, PhD

Speaker Bios Cdc-pdf[PDF – 2 pages]

Organizing Committee

Saleem Kamili, PhD 
Division of Viral Hepatitis, CDC 

John W. Ward, MD 
Division of Viral Hepatitis, CDC 

Anne M. Gaynor, PhD 
Association of Public Health Laboratories 

Claudia Denkinger, MD 
Foundation for Innovative New Diagnostics